U.S. Markets closed

Shareholders Are Thrilled That The FibroGen (NASDAQ:FGEN) Share Price Increased 165%

Simply Wall St

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

FibroGen, Inc. (NASDAQ:FGEN) shareholders might be concerned after seeing the share price drop 15% in the last quarter. But in three years the returns have been great. In fact, the share price is up a full 165% compared to three years ago. After a run like that some may not be surprised to see prices moderate. Only time will tell if there is still too much optimism currently reflected in the share price.

Check out our latest analysis for FibroGen

FibroGen isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

FibroGen actually saw its revenue drop by 0.6% per year over three years. So the share price gain of 38% per year is quite surprising. It's a good reminder that expectations about the future, not the past history, always impact share prices.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

NasdaqGS:FGEN Income Statement, July 10th 2019

Take a more thorough look at FibroGen's financial health with this free report on its balance sheet.

A Different Perspective

FibroGen shareholders are down 31% for the year, but the broader market is up 6.4%. Of course the long term matters more than the short term, and even great stocks will sometimes have a poor year. Investors are up over three years, booking 38% per year, much better than the more recent returns. Sometimes when a good quality long term winner has a weak period, it's turns out to be an opportunity, but you really need to be sure that the quality is there. You could get a better understanding of FibroGen's growth by checking out this more detailed historical graph of earnings, revenue and cash flow.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.